Which countries run stem-cell trials for Crohn's & IBD?
The geography spans 26 countries and is concentrated: United States carries roughly 36% of the country mentions (2026-08-29).
Country distribution
| Country | Studies with a site there |
|---|---|
| United States | 35 |
| Spain | 13 |
| France | 10 |
| South Korea | 7 |
| Italy | 7 |
| Belgium | 7 |
| China | 6 |
| Israel | 5 |
| Austria | 4 |
| Germany | 4 |
A study with sites in several countries is counted once per country, taken from the location block of each registry record.
What the map means for Crohn's & IBD
European centres are prominent because a locally administered adipose-derived product went through EMA review for perianal fistulas, creating regulatory and clinical expertise around that indication specifically. That geography does not transfer to intravenous offers for general IBD.
Where recruitment is actually open
| Country | Open studies with a site there |
|---|---|
| United States | 4 |
| France | 3 |
| Malaysia | 1 |
| Belgium | 1 |
| China | 1 |
What travelling for a trial actually involves
Before treating a foreign site as an option, confirm the follow-up burden in writing. Trials measure outcomes on a schedule; missing those visits makes the data unusable and leaves you outside the safety net the protocol provides.
Multi-country studies, named
Registered studies with sites in more than one country — the clearest evidence of collaboration rather than a single-centre series.
No sampled study for this condition lists sites in more than one country, so the research base here is made of single-centre work rather than multinational collaboration.
Why trial geography is not a shortlist
The map is drawn by policy and money. Permissive or well-defined regulatory pathways attract registrations and large research budgets attract more still. None of that transfers to the private clinic advertising in the same city, which may operate under no comparable supervision.
Before treating geography as a shortlist, read the legality overview by country and what "best country" actually means here.
When these studies started
Registrations by start year since 2020: 2020 (8), 2021 (4), 2022 (9), 2023 (4), 2024 (3), 2025 (6), 2026 (2). Activity for this condition spans 2001 to 2026, which shows whether interest is growing, flat or past its peak.
Frequently asked
Which countries run stem-cell trials for Crohn's & IBD?
Sites are registered in 26 countries; the largest is United States (~36% of country mentions, 2026-08-29).
Does a country with many trials mean better treatment there?
No. Registration volume reflects the research and regulatory environment, not the quality of care a private clinic there will provide.
Are trial sites and commercial clinics the same thing?
They are generally distinct. Proximity in a city or even a shared address does not make a commercial clinic part of a registered protocol — ask for the identifier.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.